Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Dominion Energy Inc (D) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Dominion Energy Inc — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $303 (market cap $39.89B), while Dominion Energy Inc trades at $69.98 (market cap $61.64B). The key difference: Dominion Energy Inc is the larger of the two by market cap, and Dominion Energy Inc pays a 3.81% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | D | |
|---|---|---|
Market Cap | $39.89B | $61.64B |
Sector | Health | Utilities |
52-Week High | $491.22 | $70.08 |
52-Week Low | $278.09 | $56.55 |
Enterprise Value | $38.15B | $114.04B |
Dividend Yield | — | 3.81% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
Dominion Energy (D) trades at $70.08, up 0.91% today, near its consensus price target of $69.50. The stock shows bullish technical signals with strong moving average support and recent earnings beats. Revenue grew to $16.51B in 2025 with net income margin expanding to 18.16%. The pending $66.8B acquisition by NextEra Energy dominates news flow, positioning Dominion as key infrastructure for AI data center power demand.
Investment outlook balances acquisition premium potential against regulatory approval risks. Strong profitability trends and strategic positioning in power infrastructure support upside, but deal uncertainty and high debt levels pose near-term volatility. Wall Street sentiment is cautious with 59% hold ratings, reflecting wait-and-see approach pending merger resolution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Dominion Energy Inc
Based in Richmond, Virginia, Dominion Energy is an integrated energy company with over 30 gigawatts of electric generation capacity and more than 90,000 miles of electric transmission and distribution lines. Dominion owns a liquefied natural gas export facility in Maryland and is constructing a 5.2 GW wind farm off the Virginia Beach coast.
Read more on D →
